|
TSC22D2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.00889999974119E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.22540000053229E-07 |
| Normal-vs-Stage2 |
2.54210000050215E-07 |
| Normal-vs-Stage3 |
3.53240000028343E-07 |
| Normal-vs-Stage4 |
1.08690000000244E-07 |
| Stage1-vs-Stage2 |
2.747600E-01 |
| Stage1-vs-Stage3 |
3.618800E-01 |
| Stage1-vs-Stage4 |
4.105800E-02 |
| Stage2-vs-Stage3 |
7.369400E-01 |
| Stage2-vs-Stage4 |
6.795600E-01 |
| Stage3-vs-Stage4 |
3.753000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.22819999965374E-07 |
| Normal-vs-AfricanAmerican |
1.97310999999756E-05 |
| Normal-vs-Asian |
2.63650000054128E-07 |
| Caucasian-vs-AfricanAmerican |
5.053400E-01 |
| Caucasian-vs-Asian |
3.069600E-01 |
| AfricanAmerican-vs-Asian |
1.879810E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.43779999964389E-07 |
| Normal-vs-Female |
5.35179999983093E-07 |
| Male-vs-Female |
3.053400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.19649999996696E-06 |
| Normal-vs-Age(41-60Yrs) |
2.18860000011922E-07 |
| Normal-vs-Age(61-80Yrs) |
1.60569999962945E-07 |
| Normal-vs-Age(81-100Yrs) |
7.742100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.339700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.522100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.610600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.808400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.935200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.571000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.429700E-02 |
| Classical-VS-Follicular |
3.013000E-04 |
| Classical-VS-Other |
5.244600E-01 |
| Classical-VS-Normal |
1.82680000004876E-06 |
| Tall-VS-Follicular |
2.901600E-01 |
| Tall-VS-Other |
9.687000E-01 |
| Tall-VS-Normal |
3.56619999974939E-07 |
| Follicular-VS-Other |
5.441000E-01 |
| Follicular-VS-Normal |
5.24959999914643E-08 |
| Other-VS-Normal |
4.17600000002238E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.33739999963467E-07 |
| Normal-vs-N1 |
2.85239999953113E-07 |
| N0-vs-N1 |
7.282200E-01 |
|
|
